Rye grass tolerising peptide vaccine - Acambis

Drug Profile

Rye grass tolerising peptide vaccine - Acambis

Alternative Names: Hay fever vaccine - Acambis; PTL 0901

Latest Information Update: 17 Feb 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Acambis
  • Class
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Seasonal allergic rhinitis

Most Recent Events

  • 17 Feb 2000 A clinical study has been added to the Vaccines therapeutic trials section
  • 22 Nov 1999 Discontinued-II for Seasonal allergic rhinitis in United Kingdom (Intranasal)
  • 13 Oct 1999 SmithKline Beecham's option to license the rye grass tolerising peptide has now expired
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top